STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial
A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.
Story detail
Read the key details here, then continue on the original publisher.
A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.
Join our channel to receive the latest headlines and breaking stories as soon as they are published.
Comments (0)
Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.
No comments yet. Be the first to share your thoughts!